https://platum.kr/archives/186160
Bio风投企业 RudaCure has secured a Series A investment of KRW 6 billion.
RudaCure is primarily developing 干眼症 and 慢性疼痛治疗药s. The Series A round included 翰林制药, Y&Archer Co., Ltd., and CKD Venture Capital as participating investors.
The investors stated that they decided to invest after highly evaluating the commercialization potential of RudaCure's 干眼症治疗药 'RCI001,' recognizing its faster 泪液分泎 疗效, 角膜损伤恢复 capability, and superior 滴眼顺应性 and safety compared to commercially available competing drugs.
The 干眼症治疗药 market has been growing steadily due to the recent advancement of digital technology and the widespread adoption of vision correction procedures. RudaCure's 'RCI001' achieves rapid drug onset while significantly reducing 副作用 such as 眼内压升高.
